MBX Biosciences files intention to go public
The five-year-old, clinical-stage drugmaker has already raised more than $213 million to develop therapeutics to treat rare endocrine disorders, a huge amount for a startup.
The five-year-old, clinical-stage drugmaker has already raised more than $213 million to develop therapeutics to treat rare endocrine disorders, a huge amount for a startup.
Purdue and Notre Dame will meet on a football field for the 126th time on Sept. 14, and while every sporting event presents the possibility of a life-changing experience, it’s unlikely anything as momentous as what happened 47 years ago will occur.
The five-year-old company is developing treatments for endocrine and metabolic disorders, such as hypoparathyroidism, post-bariatric hypoglycemia and obesity. Its positive reception on Wall Street was seen as an extension of the general enthusiasm for obesity treatments.
Last month, a federal agency determined “with moderate confidence” that there is a link between higher levels of fluoride exposure and lower IQ in kids.